These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9563068)

  • 21. Are the current bioequivalence standards sufficient for the acceptance of narrow therapeutic index drugs? Utilization of a computer simulated warfarin bioequivalence model.
    Walker SE; Friesen MH
    J Pharm Pharm Sci; 1999; 2(1):15-22. PubMed ID: 10951658
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I).
    Fernández-Teruel C; Nalda Molina R; González-Alvarez I; Navarro-Fontestad C; García-Arieta A; Casabó VG; Bermejo M
    Eur J Pharm Sci; 2009 Jan; 36(1):137-46. PubMed ID: 19028574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bioequivalence: performance of several measures of extent of absorption.
    Bois FY; Tozer TN; Hauck WW; Chen ML; Patnaik R; Williams RL
    Pharm Res; 1994 May; 11(5):715-22. PubMed ID: 8058642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exposure measures applied to the bioequivalence of two sustained release formulations of bupropion.
    Midha KK; Rawson MJ; McKay G; Hubbard JW
    Int J Clin Pharmacol Ther; 2005 May; 43(5):244-54. PubMed ID: 15906590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pivotal Bioequivalence Study of Clopacin®, a Generic Formulation of Clopidogrel 75 mg Film-Coated Tablets.
    McGregor GP
    Adv Ther; 2016 Feb; 33(2):186-98. PubMed ID: 26825365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the bioequivalence of highly-variable drugs and drug products.
    Tothfalusi L; Endrenyi L; Midha KK; Rawson MJ; Hubbard JW
    Pharm Res; 2001 Jun; 18(6):728-33. PubMed ID: 11474774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Subject-by-formulation interaction in determinations of individual bioequivalence: bias and prevalence.
    Endrenyi L; Tothfalusi L
    Pharm Res; 1999 Feb; 16(2):186-90. PubMed ID: 10100301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biometrical evaluation of bioequivalence trials using a bootstrap individual direct curve comparison method.
    Zintzaras E; Bouka P; Kowald A
    Eur J Drug Metab Pharmacokinet; 2002; 27(1):11-6. PubMed ID: 11996322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of truncated areas in the assessment of bioequivalence of immediate release formulations of drugs with long half-lives and of Cmax with different dissolution rates.
    Sathe P; Venitz J; Lesko L
    Pharm Res; 1999 Jun; 16(6):939-43. PubMed ID: 10397617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers.
    Parrillo-Campiglia S; Ercoli MC; Umpierrez O; Rodríguez P; Márquez S; Guarneri C; Estevez-Parrillo FT; Laurenz M; Estevez-Carrizo FE
    Clin Ther; 2009 Oct; 31(10):2224-32. PubMed ID: 19922893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A replicate study design for testing bioequivalence: a case study on two desmopressin nasal spray preparations.
    Joukhadar C; Schenk B; Kaehler ST; Kollenz CJ; Bauer P; Müller M; Eichler HG
    Eur J Clin Pharmacol; 2003 Nov; 59(8-9):631-6. PubMed ID: 14564429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative study on the bioequivalence of two formulations of pravastatin. Data from a crossover, randomised, open-label bioequivalence study in healthy volunteers.
    Almeida S; Filipe A; Almeida A; Gich I; Antonijoan R; Puntes M; Barbanoj M; Cruz Caturla M
    Arzneimittelforschung; 2006; 56(2):70-5. PubMed ID: 16572920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic properties and bioequivalence of 2 formulations of valsartan 160-mg tablets: A randomized, single-dose, 2-period crossover study in healthy Korean male volunteers.
    Kim JE; Ki MH; Yoon IS; Cho HJ; Kim RS; Tae Kim G; Kim DD
    Clin Ther; 2014 Feb; 36(2):273-9. PubMed ID: 24529292
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-Dose Comparative Pharmacokinetics of Two Formulations of Lenalidomide 25 mg in Healthy Subjects: A Randomized Crossover Study.
    Lee S; Hwang JG; Park SY; Lim HJ; Lee SW; Seo MH; Kim J; Hong JH
    Adv Ther; 2018 Feb; 35(2):210-217. PubMed ID: 29411269
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Confidence intervals for ratios of AUCs in the case of serial sampling: a comparison of seven methods.
    Jaki T; Wolfsegger MJ; Ploner M
    Pharm Stat; 2009; 8(1):12-24. PubMed ID: 18407562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimation in AB/BA crossover trials with application to bioequivalence studies with incomplete and complete data designs.
    Jaki T; Pallmann P; Wolfsegger MJ
    Stat Med; 2013 Dec; 32(30):5469-83. PubMed ID: 23801551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using partial area for evaluation of bioavailability and bioequivalence.
    Chen ML; Davit B; Lionberger R; Wahba Z; Ahn HY; Yu LX
    Pharm Res; 2011 Aug; 28(8):1939-47. PubMed ID: 21487930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sample Size Determination and Study Design Impact on Dose-Scale Pharmacodynamic Bioequivalence: a Case Study Using Orlistat.
    Xu L; Li S; Wu W; Cheng Z; Xie F
    AAPS J; 2024 Jul; 26(4):77. PubMed ID: 38960976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of length of sampling schedule and washout interval on magnitude of drug carryover from period 1 to period 2 in two-period, two-treatment bioequivalence studies and its attendant effects on determination of bioequivalence.
    Dhariwal K; Jackson A
    Biopharm Drug Dispos; 2003 Jul; 24(5):219-28. PubMed ID: 12784322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tmax: an unconfounded metric for rate of absorption in single dose bioequivalence studies.
    Basson RP; Cerimele BJ; DeSante KA; Howey DC
    Pharm Res; 1996 Feb; 13(2):324-8. PubMed ID: 8932457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.